Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that CEO Axel Bolte will be part of the Neuromuscular and Bone Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, from 2:10-3:10 pm ET in Boston. The event will highlight the company’s innovative therapeutic initiatives aimed at treating pathologic mineralization and intimal proliferation. A replay of the panel will be available on their Investor Relations page for a limited time after the event. Inozyme is developing INZ-701, currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies.
Details
News Market Reaction – INZY
The recorded move for INZY in the trading session of this news was +7.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the Neuromuscular and Bone Panel presentation at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, from 2:10-3:10pm ET in Boston.
A replay of the panel presentation can be accessed from the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.
About Inozyme Pharma
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.